Hyperalgesia News and Research

RSS

Study evaluates distribution and severity of pain in sexual assault victims

A majority of sexual assault victims experience severe pain in the early aftermath of the crime but less than a third of these victims receive pain medications, according to research in The Journal of Pain, the peer review publication of the American Pain Society.

12 Sep 2012

Potassium-channel autoimmunity linked to chronic pain

A substantial proportion of patients with voltage-gated potassium channel-complex autoimmunity experience chronic idiopathic pain, although the specific antigenic complex associated with pain remains to be determined, conclude US scientists.

3 Sep 2012

Chronic nerve pain: an interview with Professor Sally Lawson

Chronic nerve pain results from pathological changes within a nerve that appear to be self-sustaining and thus the pain continues for a long time.

30 Aug 2012

Opiate addiction disorders associated with opioid-induced hyperalgesia

Patients with addictive disorders who take methadone or other opioid medications for pain will experience heightened sensitivity to pain, known as hyperalgesia, and new research published in The Journal of Pain shows that the condition does not improve over the course of treatment.

23 Apr 2012

Study clarifies ginkgo's pain-reducing effects

Experiments in rats show that a standardized ginkgo extract—injected either into the spinal canal or directly into the injured area—effectively reduces inflammation and some types of pain, according to a report in the May issue of Anesthesia & Analgesia, official journal of the International Anesthesia Research Society.

28 Apr 2011

New findings may make morphine a safer, more effective drug for chronic pain control

An orphan drug originally used for HIV treatment has been found to short-circuit the process that results in additional sensitivity and pain from opioid use. The study by researchers at the Indiana University School of Medicine is reported in the March 25, 2011 issue of Brain, Behavior and Immunity.

25 Mar 2011

Waismann Method examines link between chronic pain and Opioid-Induced Hyperalgesia

Results from a recent study issued by the Substance Abuse & Mental Health Services Administration revealed that treatment admissions for prescription painkiller abuse rose 345 percent over a 10 year period extending from 1998 to 2008.

5 Feb 2011

New study reports close association between obesity and fibromyalgia

Afflicting up to 5 percent of the U.S. population, mostly women, fibromyalgia is characterized by widespread pain and range of function problems. A new study in The Journal of Pain reports there is close association between obesity and disability in fibromyalgia patients.

29 Dec 2010

Scientists suggest targeting ion channels could offer effective pain relief

University at Buffalo neuroscience researchers conducting basic research on ion channels have demonstrated a process that could have a profound therapeutic impact on pain.

20 Dec 2010

Waismann Method survey: 88% of individuals taken prescription painkillers for chronic pain relief

According to a recent survey conducted by the Waismann Method of opiate detoxification, doctors prescribing medication for the treatment of chronic pain were found to be the leading source of prescription painkiller use. Approximately 88 percent of all respondents stated they began taking prescription painkillers for chronic pain relief, with an astounding 70 percent of these individuals believing that they experience the same or a greater amount of pain than when originally prescribed painkillers.

11 Jun 2010

Gastrointestinal tract disorders GERD and IBS interlinked

Gastroesophageal reflux disorder (GERD) and irritable bowel syndrome (IBS) are two very common disorders affecting the gastrointestinal tract. About 10% of the population experience daily discomfort from reflux of gastric contents into the esophagus. More than 10% of the population experience abdominal pain and disturbed bowel movement because of irritable bowel syndrome.

2 Apr 2010

Raptor Pharmaceutical announces results of NGX426 clinical trial

Raptor Pharmaceutical Corp. today announced the presentation of clinical trial data on NGX426, the Company's orally administered, non-opioid, AMPA/kainate receptor antagonist, at the 12th International Conference on the Mechanisms and Treatment of Neuropathic Pain, held on November 20-21 in San Francisco.

23 Nov 2009

Raptor Pharmaceutical to present oral AMPA-kainate antagonist data at the neuropathic pain conference

Raptor Pharmaceutical Corp., today announced that data from a clinical trial of NGX426, the Company's orally administered non-opioid, AMPA/kainate antagonist, will be presented at the 12th International Conference on the Mechanisms and Treatment of Neuropathic Pain, to be held November 20-21, 2009 in San Francisco.

5 Nov 2009

Endocannabinoids found to spread and prolong pain

Imagine that you're working on your back porch, hammering in a nail. Suddenly you slip and hit your thumb instead - hard. The pain is incredibly intense, but it only lasts a moment. After a few seconds (and a few unprintable words) you're ready to start hammering again.

13 Aug 2009

Compound from coral offers hope fpr neuropathic pain

A compound initially isolated from a soft coral (Capnella imbricata) collected at Green Island off Taiwan, could lead scientists to develop a new set of treatments for neuropathic pain - chronic pain that sometimes follows damage to the nervous system.

4 Aug 2009

Opioid antagonists show potential for problematic pain

Achieving effective, durable, and safe pain relief, especially in patients with chronic and/or severe pain conditions, can be difficult.

2 Apr 2009

Opioid antagonists help pain management

Achieving effective, durable, and safe pain relief, especially in patients with chronic and/or severe pain conditions, can be difficult.

3 Mar 2009

Leconotide, an investigative calcium channel blocker, shows potential as pain treatment

Results of a pre-clinical study of leconotide, an investigative calcium channel blocker, shows it has the potential to be safe, selective, and efficacious as a new non-opioid treatment for pain relief. It also holds promise in multiple drug delivery options including nasal spray, transdermal patch, and pills. Data were presented today at the American Academy of Pain Medicine's 25th Annual Meeting.

29 Jan 2009

KAI Pharmaceuticals reports positive results for KAI-1678 in pain reduction

KAI Pharmaceuticals, Inc., a privately held drug discovery and development company, today announced preclinical results demonstrating the effectiveness of KAI-1678 in reversing pain (hyperalgesia and allodynia) in multiple preclinical models.

19 Nov 2008